THERAPY TO PREVENT HEPATOCELLULAR CARCINOMA IN PEOPLE WITH LIVER CIRRHOSIS
Professor John Olynyk, Liver Specialist, Gastroenterologist & Hepatologist,
Fiona Stanley and Fremantle Hospitals
South Metropolitan Health Service, Western Australia &
Associate Director, Clinical Engagement,
Curtin Medical Research Institute, Curtin University, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Professor John Olynyk is a Gastroenterologist & Hepatologist with over 30 years’ experience, primarily at The Fiona Stanley & Fremantle Hospital Group. He planned the Gastroenterology and Hepatology Service for the Fiona Stanley Hospital and was Head Department from 2010 until 2020.
Professor John Olynyk was appointed as Associate Dean and Head of the Medical Discipline at Curtin University in 2023 until 2025 and is now Associate Director, Clinical Engagement, Curtin Medical Research Institute, Curtin University.
Professor John Olynyk has a long and productive history of research in the field of haemochromatosis, liver disease and iron metabolism. He has sustained 27 years of continuous funding from the NHMRC and published over 270 peer reviewed publications with nearly 20,000 citations. He is patron of Haemochromatosis Australia and currently serves on the Royal Australasian College of Physicians overseas trained physicians assessment panel.
He has been a member of multiple national and international professional organisations. He was a keynote speaker at the UK Liver Cancer Meeting at Cambridge University in 2024. Currently he is leading a multicentre, international NHMRC-funded clinical trial examining whether aspirin therapy can prevent hepatocellular carcinoma in people with cirrhosis.
Source: Supplied
https://orcid.org/0000-0003-0417-3411
-
Optimising Rural Musculoskeletal Health
Adnan Asger Ali is a Director of Accelerate Physiotherapy and PhD candidate at The University of Sydney, where he is researching implementation strategies for musculoskeletal care pathways in rural Australia as part of the PACE-RURAL project.
A passionate advocate for physiotherapy, Adnan serves as Chair of the Australian Physiotherapy Association’s National Musculoskeletal Committee and sits on the Capital Health Network’s Clinical Council. His commitment to clinical excellence was recognised when he received Physiotherapist of the Year at the 2023 Allied Health Awards.
-
Indigenous Australian health and ear disease
Professor Kelvin Kong feels incredibly fortunate to lead a fulfilling life surrounded by his loved ones. With a demonstrated history of service in the health industry, he brings a wealth of expertise across various sectors including clinical research, medical education, surgery, paediatrics, health policy, and Indigenous education. Kelvin started his university, residing at New College in 1992, which brings him fond memories. Graduating from medicine from the University of NSW, Kelvin continued his studies and became a fellow of the Royal Australasian College of Surgeons (RACS) and Australian Society of Otolaryngology, head & neck Society (ASOHNS).
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
